Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma Inc. (LTRN) has announced a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of the drug candidate XCE853, a protein disulfide isomerase inhibitor aimed at treating various cancer indications. This collaboration will utilize Lantern's RADR AI platform to identify biomarkers and efficacy-associated signatures for XCE853, potentially guiding future clinical development and patient selection.
May 06, 2024 | 7:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma's collaboration with Oregon Therapeutics to develop XCE853 could significantly enhance its position in oncology drug development, leveraging AI for precision medicine.
The collaboration with Oregon Therapeutics to optimize the development of XCE853 using Lantern Pharma's RADR AI platform is likely to have a positive short-term impact on LTRN's stock. This partnership not only highlights Lantern's innovative approach to drug development but also positions the company at the forefront of AI-driven oncology research. The focus on developing treatments for resistant cancers could significantly enhance the company's market position and investor perception, potentially leading to an increase in stock value.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90